Category Archives: Regenerative Medicine

ILOILO CITY, Iloilo (PIA) - Stem cell therapy is now available in Iloilo, specifically at St. Paul's Hospital (SPHI), a premier health care provider here.

The first hospital-based stem cell and regenerative medicine facility in this city was recently launched, with a signing of a memorandum of agreement (MOA) by SPHI, the MedicalConglomerate of Asia, Africa and Oceania, Inc. (MCAAO), and the Iloilo City government.

SPHI Kidney Center Head and Stem Cell medicine coordinator Dr. Helen Caro-Pastolero said the partnership venture identifies SPHI as the medical hub and the MCAAO as technology service provider, with the city government providing support for the medical tourism-categorized project.

St. Paul's hospital administrator, Sister Rosamond Marie Abadesco said ''After months of preparation and planning we are now almost ready to open this innovative program for the people of Iloilo.''

Stem cell medicine is an innovative program involving the engineering of living cells and tissue which are preserved to enhance organ functions. The therapy offers treatment for diabetes, arthritis, Parkinson's Diseases, Alzheimer's disease, among other disorders.

Mayor Jed Patrick Mabilog said the launching of SPHI's stem cell medical service ''definitely puts the city in the medical tourism industry map and gives an additional boost to Iloilo City as it gears for premier city status.

''We are fast becoming an emerging haven for businesses and investors as well as medical tourists who are keen about our services in terms of health and wellness,'' said Mabilog who also disclosed that aside from the city's positioning itself as a potential Asian Pacific Economic Cooperation (APEC) Summit host in 2015 and the Association of Southeast Asian Nations (ASEAN) Summit in 2017, he has also received communication from the United Nations (UN) ''asking if Iloilo City could host the UN Urban Environmental Accords world conference in 2016.''

Meanwhile, MCAAO Inc. president Dr. Leo Olarte said he is happy that stem cell treatment has been accepted in this part of the country because ''it is for the best interest of patients needing stem cell medical therapy.''

''We hope that our joint venture with SPHI in stem cell therapy will highlight Iloilo's potentials as an ideal medical tourism destination in this part of the country,'' said Olarte.

He informed that the SPHI stem cell facility will utilize the Autologous stem cell transplantation therapy in which stem cells (cells from which other cells of the same type develop) are removed, stored, and later given back to the same person from whom such cells were harvested.

Read the original:
Regenerative medicine now in Iloilo

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/23dgtg/regenerative) has announced the addition of the "Regenerative Medicine Markets" report to their offering.

Regenerative medicine is a way of treating injured and diseased human tissue by using laboratory-grown or therapeutically-induced human tissue as a replacement.

This TriMark Publications report discusses the current state of regenerative medicine. The study provides a thorough overview of regenerative medicine sector together with analyses of the funding trends, intellectual property, market opportunities, therapeutic pipeline, research collaborations, partnership activities, and guidelines for establishing new ventures.

The report enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions.

Key Topics Covered

1. Overview

2. Regenerative Medicines: An Overview of Segments

3. Regenerative Medicine: The Next Evolution of Medical Treatment

4. Recent Advances in Regenerative Medicine and Stem Cell Research

See the original post here:
Research and Markets: Regenerative Medicine Markets - 2013 Report

Commercialisation through collaboration - Ed Field - World Stem Cells Regenerative Medicine
Ed Field, Chief Operating Officer at Cytomedix gives his presentation on #39;Commercialisation through collaboration: what does partnering in this industry actu...

By: biopharmachannel

See original here:
Commercialisation through collaboration - Ed Field - World Stem Cells Regenerative Medicine - Video

Health economics - Prof. Richard Lilford - World Stem Cells Regenerative Medicine Congress 2013
Prof. Richard Lilford, Clinical Epidemiology, Public Health Biostatistics at the University of Birmingham gives his presentation on #39;Health economics: how ...

By: biopharmachannel

Go here to read the rest:
Health economics - Prof. Richard Lilford - World Stem Cells Regenerative Medicine Congress 2013 - Video

World Courier Logistics Ltd. - World Stem Cells Regenerative Medicine Congress 2013
We spoke with some of the sponsors at Europe #39;s largest stem cells and regenerative medicine industry conference. This is a three day congress that stages a s...

By: biopharmachannel

Originally posted here:
World Courier Logistics Ltd. - World Stem Cells Regenerative Medicine Congress 2013 - Video

Alternative financing models - Navid Malik - World Stem Cells Regenerative Medicine Congress
Navid Malik, Head of Life Science Research at Cenkos Securities gives his presentation on #39;Alternative financing models: floating on the stock markets to gai...

By: biopharmachannel

Continued here:
Alternative financing models - Navid Malik - World Stem Cells Regenerative Medicine Congress - Video

Chairman #39;s Opening Remarks - Prof. Chris Mason - World Stem Cells Regenerative Medicine Congress
Prof. Chris Mason from the Regenerative Medicine Bioprocessing Unit, Advanced Centre for Biochemical Engineering at the University College London gives the C...

By: biopharmachannel

View original post here:
Chairman's Opening Remarks - Prof. Chris Mason - World Stem Cells Regenerative Medicine Congress - Video

Instron, a leading provider of testing equipment solutions designed to evaluate mechanical properties of materials and components, is pleased to announce the acquisition of Tissue Growth Technologies (TGT), a premier supplier of commercial bioreactors to grow and stimulate developing tissues.

TGT will become part of the Instron division of ITWs Test and Measurement business. In partnership, we are excited to offer an instrumentation platform that is uniquely designed to cater to all aspects of tissue engineering. Our broad range of applications include:

condition and engineer developing tissues characterize tissue engineering components reveal fundamental mechanisms of cell function direct stem cell differentiation provide an in vitro testbed for drug and cell therapy development

Instron and TGT are excited about this new partnership. Not only is Instron gaining the knowledge and experience of TGT, but were now able to provide a full range of solutions for the tissue engineering and regenerative medicine fields, said James Ritchey, Instrons Director of Tissue Engineering Businesses.

About Instron

Instron is a leading provider of test equipment for the material and structural testing markets. A global company providing single-source convenience, Instron manufactures and services products used to test the mechanical properties and performances of various materials, components and structures in a wide array of environments.

Instron systems evaluate materials ranging from the most fragile filament to advanced high-strength alloys, providing customers with comprehensive solutions for all their research, quality and service-life testing requirements. Additionally, Instron offers a broad range of service capabilities, including assistance with laboratory management, calibration expertise and customer training.

For more information, contact Instron, 825 University Ave, Norwood, MA 02062, USA. Toll-free: 1-800-564-8378; Fax: 1-781-575-5725; or visit our website at http://www.instron.com.

About Tissue Growth Technologies

Tissue Growth Technologies is a premier supplier of tissue engineering bioreactors and associated products specifically designed for the emerging regenerative medicine market. Building on 16 years of development, TGT has developed relationships with customers in corporate, academic, and government research across the globe. The teams experienced scientists and engineers are continually looking for opportunities to assist the tissue engineering and regenerative medicine market.

Read the original post:
Strategic Acquisition Advances Regenerative Medicine

MARLBOROUGH, Mass.--(BUSINESS WIRE)--

Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that its chief scientific officer, Robert Lanza, M.D., will be delivering the Keynote Address at the BWH Regenerative Medicine Center Inaugural Symposium, being held at Brigham & Womens Hospital in Boston on June 11. The Symposium will showcase an exciting array of research in regenerative medicine; highlighting the work of both nationally and internationally recognized investigators and that of the rising stars working in this domain. Dr. Lanzas address, titled Pluripotent Stem Cells Moving From Bench to Bedside, will take place at 4 p.m. EDT in the Bornstein Family Amphitheater & Cabot Atrium.

The newly formed Regenerative Medicine Center at Brigham & Womens Hospital is a marriage of stem cell biology with state-of-the-art engineering and nanotechnology, integrating the talents of engineers, physicists and mathematicians with those of biologists and clinicians. BWH investigators are nationally and internationally recognized for their contributions to advances in stem cell, regenerative medicine and tissue engineering research as recipients of prestigious awards, including elected members of numerous scientific and medical organizations. In addition to Dr. Lanzas Keynote Address, the Symposium will include sessions about Pluripotent Stem Cells & Basic Developmental Biology, Adult Stem Cells & Disease and Novel Technologies in Regenerative Medicine.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words will, believes, plans, anticipates, expects, estimates, and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the companys periodic reports, including the report on Form 10-K for the year ended December 31, 2012. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Companys clinical trials will be successful.

Read the rest here:
ACT’s Dr. Robert Lanza to Deliver the Keynote Address at Brigham & Women’s Hospital Regenerative Medicine Center ...

Tijuana, Mexico (PRWEB) May 27, 2013

Regenerative Medicine Institute, Mexico (RMI) recently hit the three year milestone in its clinical research trial of adult stem cells. The trial seeks to discover the impact of stem cells on degenerative conditions such as heart disease, COPD, vascular issues, orthopedic conditions, and other chronic health problems.

Regenerative Medicine is an institute of board certified, multi-specialty physicians working together to place a patients own stem cells (autologous) as close as possible to diseased organ or tissue. Utilizing specialized catheters makes this cutting-edge procedure less invasive than traditional treatments and doctors are able to get the stem cells to the most remote areas of the body. Patients are awake for the entire procedure, which usually lasts less than an hour.

At the age of 65, Dean Stokes feels as though RMI has given him a new lease on life. I used to get up in the morning, get ready, and go to work. Now I get up in the morning, get ready, and go to the gym, Stokes said.

Things were very different three years ago as Stokes recovered from a heart attack. Treated on June 10, 2010, Stokes was one of the first patients enrolled in the stem cell trial at RMI. Once I got there, I felt extremely comfortable. The facility was first class. I could look out the window and see kids playing at school, and see parents waiting to pick their kids up.

Stokes says that he felt better immediately after his stem cell procedure, both physically and mentally. Stokes took two walking tests the day prior to his stem cell treatment. He was able to walk 495 meters in the first session and 456 meters during the second. Three months later he was tested again. By then, he was able to walk 615 meters during one session, and 690 meters in another.

The very first patient to enroll in RMIs trial was Lynn Munson. In a few short years, Munson says that her life became a shadow of what it had once been. COPD had robbed Munson of her health and ability to do the things she longed to do. "Going to Tijuana was a last-ditch effort, Munson said. I told my husband that I wanted to die at home, not in some airport. He encouraged me and promised to get me where I need to be quickly."

Today, Munson says that she doesnt give much thought to being the first patient enrolled at RMI. "I'm just so thankful for the way I feel and the way I can breathe," she said.

Morton Farina is another trial participant. Although he underwent successful bypass surgery years ago, Farina suffered another heart attack 12 years later. He went to work discovering what his alternatives were. A physician friend suggested he look into RMI.

We went down on a Sunday night. They did the liposuction the same night and injected stem cells directly into 27 different areas of my heart, using a catheter through the groin, Farina said.

Continued here:
Regenerative Medicine Institute, Mexico Reaches Three Year Milestone